|
|
| | 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl- Basic information |
| Product Name: | 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl- | | Synonyms: | 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl-;KF 26777;KF26777;KF-26777 | | CAS: | 206129-88-6 | | MF: | C16H16BrN5O | | MW: | 374.24 | | EINECS: | | | Product Categories: | | | Mol File: | 206129-88-6.mol | ![5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl- Structure](CAS/20210305/GIF/206129-88-6.gif) |
| | 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl- Chemical Properties |
| Boiling point | 582.2±56.0 °C(Predicted) | | density | 1.69±0.1 g/cm3(Predicted) | | pka | 10.90±0.20(Predicted) |
| | 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl- Usage And Synthesis |
| Uses | KF26777 (free base) is a potent and selective adenosine A3 receptor antagonist with an Ki value of 0.2 nM and possesses 9000-, 2350- and 3100-fold selectivity against adenosine A1, A2A and A2B receptors, respectively. KF26777 (free base) potently inhibits the [125I]AB-MECA binding to adenosine A3 receptors. KF26777 (free base) is promising for research of brain ischemia and inflammatory disease including asthma[1]. | | References | [1] Saki M, et al. KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol. 2002 May 31;444(3):133-41. DOI:10.1016/s0014-2999(02)01662-x |
| | 5H-Imidazo[2,1-i]purin-5-one, 2-(4-bromophenyl)-3,4,7,8-tetrahydro-4-propyl- Preparation Products And Raw materials |
|